Chonluten Research & Listing Availability

Current Chonluten vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.

Current Chonluten vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.

About Chonluten

Pre-clinical / research-onlyAlso known as: Glu-Asp-Gly · EDG

Chonluten is a synthetic Glu-Asp-Gly (EDG) tripeptide from the Khavinson program, sourced for bronchial/pulmonary-tissue and aging research. It ships as a lyophilized powder you reconstitute before use, so the real vendor difference is what the certificate of analysis (COA) shows.

What to check before you buy Chonluten:

  • A third-party COA showing ≥98% purity by HPLC plus mass-spec confirmation of the EDG tripeptide.
  • A COA dated within the last 6–12 months matching the exact vial size and batch you are buying.
  • Accurate vial fill matching the labeled amount. Under-filled or mislabeled vials are a common failure mode and throw off your dose math.

Russian single-site studies have reported Chonluten as an adjunct in chronic bronchopulmonary pathology — chronic bronchitis, COPD, and post-pneumonia rehabilitation in elderly patients — with reported improvements in symptom scores and pulmonary-function tests versus standard care.[3] These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.

Regulatory: Not FDA-approved for any indication. Sold in Russia as a non-prescription dietary peptide; research-grade injectable material elsewhere.

Read the full mechanism & research breakdown

Chonluten: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Chonluten works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

Chonluten is a synthetic tripeptide — Glutamate-Aspartate-Glycine (Glu-Asp-Gly, EDG) — developed by Vladimir Khavinson's laboratory as the proposed active fragment of a bovine bronchial-tissue extract, framed in the Khavinson catalogue as a shorter, pulmonary-specific companion to the tetrapeptide Bronchogen (Ala-Glu-Asp-Leu).[1][4] The proposed mechanism is direct binding to gene-promoter DNA in bronchial epithelial and pulmonary cells, selectively modulating transcription of genes involved in mucosal repair, ciliated-cell turnover, and local antioxidant defense — rather than binding to a conventional cell-surface receptor.[2] **This mechanism is unconventional and remains poorly characterised outside the originating laboratory.** Direct sequence-specific binding of a three-amino-acid peptide to a gene-promoter region is not a recognised mode of action in mainstream molecular biology, and no laboratory outside the Khavinson group has published independent replication or biochemical characterisation of the proposed promoter-binding activity for Chonluten specifically. Meaningful English-language community discussion is effectively absent; typical research-grade protocols run 1–2 mg subcutaneous daily for 10–20-day courses, repeated once or twice per year.

Active research areas

  • Adjunct in chronic bronchopulmonary pathology (Russian observational)
    Single-site Russian studies have reported Chonluten as an adjunct in elderly patients with chronic bronchitis, COPD, and post-pneumonia rehabilitation, with reported improvements in symptom scores and pulmonary-function tests versus standard care.[3] The studies are non-blinded, single-site, and run by groups affiliated with the originating laboratory.
  • Short-peptide bioregulator programme (mechanism context)
    Chonluten sits inside the broader Khavinson peptide-bioregulator framework summarised in the group's Biogerontology 2010 review and the 2002 Neuro Endocrinol Lett supplement.[1][4]
  • No Western Phase 2 or 3 programme
    No Phase 2 or Phase 3 trial of Chonluten has been registered on ClinicalTrials.gov or in the EU Clinical Trials Register, and no Western academic group has published an independent characterisation of the molecule in any pulmonary indication.[1][3][4]
Open questions & leading hypotheses (2)
  • Hypothesis: Cyclic Chonluten courses improve pulmonary function in elderly bronchopulmonary patients.
    Evidence: The Khavinson-affiliated Russian reports describe symptom-score and spirometry improvements versus standard care.[3] Counter-evidence: non-blinded, single-site, originating-laboratory cohorts; no independent replication; no Western Phase 2 or 3 trial; modern respiratory-trial standards require placebo-controlled designs that the published Chonluten literature does not meet.
  • Hypothesis: Chonluten and Bronchogen act on the same bronchial mechanism, distinguished only by sequence length.
    Evidence: Both are catalogued in the Khavinson framework as bronchial peptide bioregulators with shared proposed mechanism.[1][4] Counter-evidence: no published head-to-head pharmacology study has compared the two molecules, and no independent group has demonstrated that the proposed promoter-binding activity is real for either.
Sources & references (4)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett 2002;23(suppl 3):11–144. · PMID: 12374906 link
  2. [2]Khavinson VKh et al. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med 2013;154:403–410. · PMID: 23484209 link
  3. [3]Kuznik BI, Khavinson VKh et al. Use of peptide bioregulators in chronic bronchopulmonary pathology in elderly patients. Adv Gerontol 2012;25:445–453.
  4. [4]Khavinson VKh, Anisimov VN et al. Peptide bioregulation of aging: results and prospects. Biogerontology 2010;11:139–149. · PMID: 19830585 link

Chonluten Calculator Input Observations

There is insufficient calculator evidence here to describe a common Chonluten entered amount. Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length.

About Chonluten

Chonluten is a synthetic Glu-Asp-Gly (EDG) tripeptide from the Khavinson program, sourced for bronchial/pulmonary-tissue and aging research. It ships as a lyophilized powder you reconstitute before use, so the real vendor difference is what the certificate of analysis (COA) shows.

Chonluten is tracked under the Recovery Peptides category on WPA. Its reported half-life is ~few hours (bioregulator estimate). Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved for any indication.

Frequently Asked Questions: Chonluten

Are current Chonluten offers available?

Current Chonluten vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.

What can I check if Chonluten listings become available?

Check the exact compound, format, labelled quantity, named laboratory, test date, and batch match. Confirm any future listing price, discount terms, and stock directly with the vendor. Catalog COA fields alone are not independent verification.

Does research activity establish current Chonluten availability?

No. Search interest, calculator entries, historical prices, related compounds, and other formats do not establish current offers in this comparison. Research information and navigation to other compounds remain available.